CD52
CD52 Molecule Information
Name：CAMPATH-1 antigen
Target Synonym：He5?CAMPATH-1 antigen?CD52?CDW52 ?HE5?CDw52?Cambridge pathology 1 antigen?Human epididymis-specific protein 5?CD_antigen=CD52?Epididymal secretory protein E5
Number of Launched Drugs：1
Number of Drugs in Clinical Trials：4
Lastest Research Phase：Approved
CD52 Molecule Synonym Name
CDW52,HE5,CD52,CAMPATH-1 antigen
CD52 Molecule Background
CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.
CD52 References
CD52 Public Drug Information
| Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
| Alemtuzumab |
CAMPATH-1H; GZ-402673; LDP-03 |
Approved |
Bayer, Genzyme |
LEMTRADA |
fda |
Multiple sclerosis (MS), Chronic lymphocytic leukemia (CLL) |
GENZYME |
2001-05-07 |
Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS) |
Details
|
CD52 Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| Campath-1G |
|
Phase Ⅱ |
University of Cambridge, GlaxoSmithKline |
Graft versus host disease, Transplant rejection |
Details
|
| GZ-402668 |
GLD-52; GZ-402668 |
Phase Ⅰ |
Genzyme |
Multiple sclerosis (MS) |
Details
|
| Recombinant anti-CD52 humanized monoclonal antibody (Shanghai Zhangjiang Biotechnology) |
|
Phase Ⅱ |
Shanghai Zhangjiang Biotechnology |
Chronic lymphocytic leukemia (CLL) |
Details
|
| Recombinant anti-CD52 humanized monoclonal antibody (Hisun Pharm) |
|
IND Filing |
Hisun Pharm |
Chronic lymphocytic leukemia (CLL) |
Details
|
A-Z
